169 related articles for article (PubMed ID: 34732618)
41. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.
Loudin MG; Wang J; Leung HC; Gurusiddappa S; Meyer J; Condos G; Morrison D; Tsimelzon A; Devidas M; Heerema NA; Carroll AJ; Plon SE; Hunger SP; Basso G; Pession A; Bhojwani D; Carroll WL; Rabin KR
Leukemia; 2011 Oct; 25(10):1555-63. PubMed ID: 21647151
[TBL] [Abstract][Full Text] [Related]
42. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.
Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ
J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563
[TBL] [Abstract][Full Text] [Related]
43. Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
Pennella CL; Rossi JG; Baialardo EM; Alonso CN; Guitter MR; Sánchez La Rosa CG; Millán NC; Alfaro EM; Zubizarreta PA; Felice MS
Arch Argent Pediatr; 2018 Aug; 116(4):e500-e507. PubMed ID: 30016023
[TBL] [Abstract][Full Text] [Related]
44. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.
Bassal M; La MK; Whitlock JA; Sather HN; Heerema NA; Gaynon PS; Stork LC
Pediatr Blood Cancer; 2005 Jan; 44(1):21-8. PubMed ID: 15368546
[TBL] [Abstract][Full Text] [Related]
45. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
46. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
[TBL] [Abstract][Full Text] [Related]
47. Down syndrome and acute lymphoblastic leukaemia.
Whitlock JA
Br J Haematol; 2006 Dec; 135(5):595-602. PubMed ID: 17054672
[TBL] [Abstract][Full Text] [Related]
48. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.
Chessells JM; Harrison G; Richards SM; Bailey CC; Hill FG; Gibson BE; Hann IM
Arch Dis Child; 2001 Oct; 85(4):321-5. PubMed ID: 11567943
[TBL] [Abstract][Full Text] [Related]
49. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.
Forestier E; Izraeli S; Beverloo B; Haas O; Pession A; Michalová K; Stark B; Harrison CJ; Teigler-Schlegel A; Johansson B
Blood; 2008 Feb; 111(3):1575-83. PubMed ID: 17971484
[TBL] [Abstract][Full Text] [Related]
50. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
51. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.
Palmi C; Savino AM; Silvestri D; Bronzini I; Cario G; Paganin M; Buldini B; Galbiati M; Muckenthaler MU; Bugarin C; Della Mina P; Nagel S; Barisone E; Casale F; Locatelli F; Lo Nigro L; Micalizzi C; Parasole R; Pession A; Putti MC; Santoro N; Testi AM; Ziino O; Kulozik AE; Zimmermann M; Schrappe M; Villa A; Gaipa G; Basso G; Biondi A; Valsecchi MG; Stanulla M; Conter V; Te Kronnie G; Cazzaniga G
Oncotarget; 2016 Sep; 7(37):59260-59272. PubMed ID: 27449287
[TBL] [Abstract][Full Text] [Related]
52. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
53. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
54. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
[TBL] [Abstract][Full Text] [Related]
55. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
Attarbaschi A; Morak M; Cario G; Cazzaniga G; Ensor HM; te Kronnie T; Bradtke J; Mann G; Vendramini E; Palmi C; Schwab C; Russell LJ; Schrappe M; Conter V; Mitchell CD; Strehl S; Zimmermann M; Pötschger U; Harrison CJ; Stanulla M; Panzer-Grümayer R; Haas OA; Moorman AV;
Br J Haematol; 2012 Sep; 158(6):772-7. PubMed ID: 22816614
[TBL] [Abstract][Full Text] [Related]
56. HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort.
Page EC; Heatley SL; Eadie LN; McClure BJ; de Bock CE; Omari S; Yeung DT; Hughes TP; Thomas PQ; White DL
Oncogene; 2022 Feb; 41(6):797-808. PubMed ID: 34857887
[TBL] [Abstract][Full Text] [Related]
57. Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.
Palmi C; Bresolin S; Junk S; Fazio G; Silvestri D; Zaliova M; Oikonomou A; Scharov K; Stanulla M; Moericke A; Zimmermann M; Schrappe M; Buldini B; Bhatia S; Borkhardt A; Saitta C; Galbiati M; Bardini M; Lo Nigro L; Conter V; Valsecchi MG; Biondi A; Te Kronnie G; Cario G; Cazzaniga G
Hemasphere; 2023 Jun; 7(6):e892. PubMed ID: 37304931
[TBL] [Abstract][Full Text] [Related]
58. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.
Morak M; Attarbaschi A; Fischer S; Nassimbeni C; Grausenburger R; Bastelberger S; Krentz S; Cario G; Kasper D; Schmitt K; Russell LJ; Pötschger U; Stanulla M; Eckert C; Mann G; Haas OA; Panzer-Grümayer R
Blood; 2012 Dec; 120(26):5134-42. PubMed ID: 23091296
[TBL] [Abstract][Full Text] [Related]
59. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
Russell LJ; Capasso M; Vater I; Akasaka T; Bernard OA; Calasanz MJ; Chandrasekaran T; Chapiro E; Gesk S; Griffiths M; Guttery DS; Haferlach C; Harder L; Heidenreich O; Irving J; Kearney L; Nguyen-Khac F; Machado L; Minto L; Majid A; Moorman AV; Morrison H; Rand V; Strefford JC; Schwab C; Tönnies H; Dyer MJ; Siebert R; Harrison CJ
Blood; 2009 Sep; 114(13):2688-98. PubMed ID: 19641190
[TBL] [Abstract][Full Text] [Related]
60. How I treat ALL in Down's syndrome: pathobiology and management.
Izraeli S; Vora A; Zwaan CM; Whitlock J
Blood; 2014 Jan; 123(1):35-40. PubMed ID: 24235135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
